大博医疗科技股份有限公司 2023 年第一季度报告 大博医疗科技股份有限公司 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 1 一、主要财务数据 证券代码：002901 证券简称：大博医疗 公告编号：2023-016 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3.第一季度报告是否经过审计 大博医疗科技股份有限公司 2023 年第一季度报告 2023 年第一季度报告 □ 是 √ 否 公司是否需追溯调整或重述以前年度会计数据 （二）非经常性损益项目和金额 2 单位：元 合计 □ 适用 √ 不适用 公司不存在其他符合非经常性损益定义的损益项目的具体情况。 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 □ 适用 √ 不适用 公司不存在将《公开发行证券的公 ...

Financial Performance - The total operating revenue for the first quarter was approximately CNY 431.07 million, with a net profit attributable to shareholders of CNY 111.53 million[32]. - In the second quarter, the operating revenue decreased to approximately CNY 396.95 million, while the net profit attributable to shareholders was CNY 68.37 million[32]. - The third quarter saw a slight increase in operating revenue to approximately CNY 406.84 million, but the net profit attributable to shareholders dropped to CNY 32.48 million[32]. - The fourth quarter reported a significant decline in operating revenue to approximately CNY 199.24 million, resulting in a net loss attributable to shareholders of CNY -120.16 million[32]. - The company's operating revenue for 2022 was ¥1,434,099,180.05, a decrease of 28.09% compared to ¥1,994,333,825.91 in 2021[52]. - The net profit attributable to shareholders for 2022 was ¥92,218,972.93, down 86.30% from ¥673,309,413.17 in the previous year[52]. - The basic earnings per share for 2022 was ¥0.22, a decline of 86.90% compared to ¥1.68 in 2021[52]. - The gross profit margin for the medical device manufacturing sector was 76.72%, down 7.69% from the previous year[102]. - Trauma products revenue dropped by 51.89% to ¥542,453,667.00, accounting for 37.83% of total revenue[102]. - The revenue from spinal products decreased by 16.50% to ¥472,100,781.95, representing 32.92% of total revenue[102]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -110.52 million in the first quarter, but improved to CNY 119.95 million in the second quarter[32]. - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of ¥128,444,750.90 in 2021 compared to a loss in 2022[52]. - The total cash flow from financing activities was CNY 799,200,000.00, with a net cash flow of CNY 246,810,659.80, compared to a net outflow of CNY -228,312,218.73 in the previous period[131]. - The company's cash and cash equivalents increased by CNY 78,602,714.31, ending the period with CNY 98,590,484.30, compared to CNY 19,987,769.99 at the beginning of the period[131]. - The total investment amount for the reporting period was CNY 88,371,363.01, a decrease of 36.94% compared to CNY 140,149,359.80 in the same period last year[119]. Market and Industry Trends - The orthopedic medical device industry is experiencing steady growth due to increasing demand from the aging population and rising incidence of orthopedic diseases[36]. - The orthopedic medical device industry in China is experiencing significant growth, driven by increasing demand for healthcare and government support for domestic production[62]. - The average price reduction for orthopedic trauma medical consumables in the Beijing-Tianjin-Hebei region reached 83.48% following a new round of centralized procurement[88]. - The domestic orthopedic medical device market is expected to continue expanding, with a focus on local production and innovation due to supportive national policies[62]. - The ongoing trend of domestic substitution in the orthopedic medical device market is expected to accelerate, providing substantial growth opportunities[62]. Company Strategy and Operations - The company plans to focus on expanding its market presence and enhancing its product offerings in response to favorable national policies and market demand[36]. - The company plans to continue focusing on the production and sales of high-value medical consumables, with no major changes in its main business operations reported[41]. - The company plans to expand its product lines in minimally invasive surgery, neurosurgery, and dental high-value consumables to drive long-term growth[91]. - The company aims to enhance production and operational efficiency to reduce costs and improve profit margins post-price reductions from centralized procurement[91]. - The company plans to strengthen its advantages in trauma and spinal orthopedic consumables, expanding production capacity to meet future demand and increase market share[183]. - The company aims to accelerate the production of innovative artificial joint prosthetics, targeting the fastest-growing segment in the domestic orthopedic implant market[183]. Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[3]. - The company has a governance structure that complies with relevant laws and regulations, ensuring independent financial decision-making and operations[188][193]. - The company has a board of directors consisting of 7 members, including 3 independent directors, ensuring compliance with governance standards[188]. - The management has outlined potential risks and corresponding strategies in the report, emphasizing the importance of risk awareness for investors[4]. Subsidiaries and Human Resources - The subsidiary Bo Yi Ning (Xiamen) Medical Equipment Co., Ltd. reported total assets of CNY 229,617,756.40 and net profit of CNY 6,536,047.21[156]. - The subsidiary Shi Ai De (Xiamen) Medical Equipment Co., Ltd. achieved total revenue of CNY 195,046,067.81 and net profit of CNY 39,149,377.90[156]. - The subsidiary Shenzhen World Surgical Medical Technology Co., Ltd. reported total revenue of CNY 59,301,238.50 and net profit of CNY 12,789,968.56[156]. - The company plans to continue implementing a human resources strategy focused on talent acquisition in marketing, academic promotion, R&D, production, and management to support rapid growth[161]. - The company is committed to enhancing its workforce's skills through various training opportunities, promoting employee development and satisfaction[190].

证券代码： 002901 证券简称：大博医疗 大博医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------|----------------------------------------------------------| | | ■ 特定对象调研（电话会） □分析师会议 | | | 投资者关系活动 | □ 媒体采访 ■业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 投资者开放日活动 | | | | | 国泰君安证券、宝盈基金、博时基金、大成基金、德邦基金、东 | | | | 方阿尔法基金、东吴基金、富国基金、高瓴资本、广发基金、国 | | | | | | | | 海富兰克林基金、国联安基金、国寿安保基金、国泰基金、国泰 | | 参与单位名称及 | | 君安、国投瑞银、合煦智远基金、恒生前海基金、华安基金、华 | | 人员姓名 | | 宝基金、华夏基金、汇添富基金、嘉合基金、嘉实基金、交银施 | | | ...

证券代码： 002901 证券简称：大博医疗 大博医疗科技股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |-----------------------|----------------------------|----------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | ■ 电话会议 | | | □ 其他 投资者开放日活动 | | | 参与单位名称及 | | 东吴证券、中信证券、融汇资本、天安财险、平安大华、浙商证 | | 人员姓名 | 券等 | | | 时间 | 2018 年 3 月 13 | 日下午 15：00 | | 地点 | 会议室 | | | 上市公司接待人 员姓名 | | 公司董事长、董事会秘书及投资者关系管理负责人 | | 投资者关系活动 | 互动问答： | | | 主要内容介绍 | Q ： ...

证券代码： 002901 证券简称：大博医疗 大博医疗科技股份有限公司投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 投资者开放日活动 | | | 参与单位名称及 | | 招商基金、交银施罗德基金、富国基金、国泰基金、汇添富基 | | 人员姓名 | | 金、国金证券、兴业证券、中泰证券等 | | 时间 | 2017 年 12 月 18 | 日下午 15：00 | | | | | | 地点 | 会议室 | | | 上市公司接待人 员姓名 | | 公司董事长、董事会秘书及投资者关系管理负责人 | | 投资者关系活动 | 互动问答： | | | 主 ...

证券代码： 002901 证券简称：大博医疗 大博医疗科技股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | |-----------------------|----------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 投资者开放日活动 | | | 参与单位名称及 | | 中融基金、富国基金、平安资管、明溪资管、国泰君安、东方创 | | 人员姓名 | | 投、万联证券、平安证券、新时代证券、招商证券、兴业证券、中 | | | 泰证券等 | | | 时间 | 2018 年 5 月 9 | 日下午 15:00-17：00 | | 地点 | 会议室 | | | 上市公司接待人 员姓名 | | 董事会秘书及投资者关系管理负责人 | | 投 ...

大博医疗科技股份有限公司 2022 年第三季度报告 大博医疗科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 4.审计师发表非标意见的事项 □ 适用 √ 不适用 一、主要财务数据 (一)主要会计数据和财务指标 1 证券代码：002901 证券简称：大博医疗 公告编号：2022-068 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------------------|----------------|-------------------- ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥828,018,203.47, a decrease of 2.19% compared to the same period last year[23]. - The net profit attributable to shareholders was ¥179,894,580.26, down 43.28% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥144,022,265.63, representing a 49.17% decline compared to the previous year[23]. - The net cash flow from operating activities was ¥9,426,858.66, a significant drop of 95.88% from the same period last year[23]. - Basic earnings per share decreased by 44.23% to ¥0.4371[23]. - The overall gross margin for the reporting period was 80.97%[62]. - The company experienced a 3.66% decline in gross margin for orthopedic trauma products due to centralized procurement, leading to a 23.18% decrease in revenue for these products[61]. - Revenue for orthopedic spine products increased by 23.83%, while orthopedic joint products and minimally invasive surgical products saw revenue growth of 216.29% and 56.82%, respectively[61]. - The company's operating costs rose by 30.15% to ¥157,533,129.86, attributed to the effects of centralized procurement policies[76]. - Sales expenses increased by 21.19% to ¥335,279,409.56, driven by higher personnel salaries and promotional service fees, as well as increased stock incentive costs[76]. - Management expenses surged by 43.49% to ¥54,525,355.49, mainly due to an increase in personnel leading to higher employee compensation and stock incentive costs[76]. Assets and Investments - Total assets at the end of the reporting period were ¥3,863,250,788.39, an increase of 14.30% from the end of the previous year[23]. - The net assets attributable to shareholders increased by 19.74% to ¥3,008,410,939.90[23]. - The total investment amount for the reporting period was ¥70,601,631.15, representing a 224.30% increase compared to ¥21,770,311.41 in the same period last year[90]. - The company has raised a total of ¥48,721.7 million through private placement, with ¥31,278.49 million already utilized, leaving ¥17,568.58 million unutilized[97]. - The company has pre-invested CNY 14,033.68 million in fundraising projects, with CNY 12,859.45 million allocated to the orthopedic implant consumables production line expansion project[100]. Research and Development - Research and development investment in the first half of the year amounted to ¥102,284,125.47, an increase of 53.52% year-on-year, indicating a strong commitment to innovation and new product lines[63]. - The company holds 494 patents, including 53 invention patents, 359 utility model patents, and 82 design patents, showcasing its strong R&D capabilities[67]. - The company is focusing on expanding its product lines in orthopedic implants, including hip joint prostheses and spinal fusion devices, to strengthen its market position[73]. - The company is committed to increasing R&D investment to align with industry development trends and ensure sustainable growth[111]. Market and Operations - The main business of the company involves the production, research and development, and sales of high-value medical consumables, with no significant changes reported during the period[33]. - The company has established a comprehensive marketing network across all regions in mainland China and some overseas areas, supported by over 600 sales personnel[58]. - The company continues to focus on expanding its market presence and developing new products in the medical consumables sector[44]. - The company is well-positioned to benefit from the shift of medical resources towards secondary hospitals, which are becoming increasingly important in the high-value consumables market[74]. - The company has achieved a significant presence in tertiary hospitals, enhancing its brand recognition and competitiveness against multinational companies in the high-value consumables sector[74]. Risks and Challenges - The company faces risks from high-value orthopedic consumables procurement policies, which may lead to price reductions affecting future performance[106]. - The company is also at risk from potential sales declines due to the ongoing COVID-19 pandemic and its impact on domestic and international markets[107]. - The company is closely monitoring industry policy changes that could affect the pricing and distribution of high-value consumables[108]. - The company faces high research and development costs and long product registration times for orthopedic consumables, which may impact future profitability if new products do not meet market demands[111]. Corporate Governance and Commitments - The company emphasizes the importance of intellectual property rights, as they are crucial for maintaining competitive advantage in a highly competitive orthopedic medical device market[112]. - The company has established a mechanism to ensure the fulfillment of public commitments made during its initial public offering[148]. - The company has committed to maintaining transparency in related party transactions and ensuring fair pricing based on market standards[150]. - The company has pledged to compensate investors for any direct losses incurred due to unfulfilled commitments, with measures including using its own funds for compensation[150]. - The company emphasizes the protection of shareholder and creditor rights by adhering to relevant laws and regulations, ensuring timely and accurate disclosure of significant events[135]. Shareholder Information - The largest shareholder, Changdu Dabotong Medical Investment Management Co., Ltd., holds 43.13% of the total shares, amounting to 179,928,000 shares[194]. - The second-largest shareholder, Dabotong Medical International Investment Co., Ltd., owns 22.07% of the shares, totaling 92,064,290 shares[194]. - The third-largest shareholder, Lin Zhijun, holds 19.37% with 80,807,710 shares, of which 20,201,928 shares are unrestricted[194]. - The total number of common shareholders at the end of the reporting period is 25,901[194]. - The report indicates that there are no changes in the voting rights of the shareholders[197].

大博医疗科技股份有限公司 2022 年第一季度报告全文 □ 是 √ 否 本报告期 上年同期 本报告期比上年同期增减 大博医疗科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 1 证券代码：002901 证券简称：大博医疗 公告编号：2022-028 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|-------------- ...